Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05942313 · ClinicalTrials.gov registry record

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

A clinical trial of Opioid Use Disorder and Pregnancy Related, sponsored by Ilana Hull.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT05942313: Recruiting study of Opioid Use Disorder and Pregnancy Related, sponsored by Ilana Hull.

NCT05942313 is a study of Opioid Use Disorder and Pregnancy Related that is actively recruiting participants, run by Ilana Hull. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05942313, a study of Opioid Use Disorder and Pregnancy Related, is actively recruiting participants, sponsored by Ilana Hull.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.

Primary Outcome

Measured via binary response, yes/no

Interventions

  • DRUG Buprenorphine/ Methadone exposure

Study Locations (1)

Pennsylvania

  • UPMC Magee-Womens Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-08-28
Est. Completion 2026-12-01
Ilana Hull

1 total trials

What NCT05942313 shows while recruiting

NCT05942313 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/ Methadone exposure is the first listed.

NCT05942313 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05942313 about?

NCT05942313 is a clinical study titled "Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy". This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout r...

What is the current status of trial NCT05942313?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-08-28. Estimated completion is 2026-12-01.

What conditions does trial NCT05942313 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Pregnancy Related.

What interventions are being tested in trial NCT05942313?

The interventions under investigation include: Buprenorphine/ Methadone exposure (DRUG).

Who is sponsoring clinical trial NCT05942313?

This trial is sponsored by Ilana Hull, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05942313 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05942313's enrollment target sits among peer trials

100 130th of 257 higher than 121 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01773278 · 100 participants · Phase 2

    Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05942313, the US trial registry maintained by the National Library of Medicine. NCT05942313 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.